Abstract:Background: Akebia saponin D (ASD) has a variety of biological activities and great medicinal potential, but its oral bioavailability is so low as to limit its development. Its pharmacokinetic profiles and excretion and metabolism in vivo have not been fully elucidated. This study was an attempt in this area. Methods: A simple LC-MS/MS method to simultaneously quantify ASD and its metabolites M1∼M5 in rat plasma, feces, urine and bile was established with a negative ESI model using dexketoprofen as the internal standard. Meanwhile, the UPLC-HR/MS system was used to screen all possible metabolites in the urine, feces and bile of rats, as compared with blank samples collected before administration. Absolute quantitative analysis was for M0, M3, M4, and M5, while semi-quantitative analysis was for M1, M2, and Orbitrap data. Results: The AUC 0-t values after intravenous administration of 10 mg/kg and intragastrical administration of 100 mg/kg ASD were 19.05 ± 8.64 and 0.047 ± 0.030 h*μg/ml respectively. The oral bioavailability was determined to be extremely low (0.025%) in rats. The exposure of M4 and M5 in the oral group was higher than that of M0 in the terminal phase of the plasma concentration time profile, and ASD was stable in the liver microsome incubation system of rats, but metabolism was relatively rapid during anaerobic incubation of intestinal contents of rats , suggesting that the low bioavailability of ASD might have been attributed to the poor gastrointestinal permeability and extensive pre-absorption degradation rather than to the potent first pass metabolism. This assertion was further verified by a series of intervention studies, where improvement of lipid solubility and intestinal permeability as well as inhibition of intestinal flora increased the relative bioavailability to different extents without being changed by P-gp inhibition. After intravenous administration, the cumulative excretion rates of ASD in the urine and bile were 14.79 ± 1.87%, and 21.76 ± 17.61% respectively, but only 0.011% in feces, suggesting that the urine and bile were the main excretion pathways and that there was a large amount of biotransformation in the gastrointestinal tract. Fifteen possible metabolites were observed in the urine, feces and bile. The main metabolites were ASD deglycosylation, demethylation, dehydroxylation, decarbonylation, decarboxylation, hydroxylation, hydroxymethylation, hydroxyethylation and hydrolysis. Conclusion: The pharmacokinetics, bioavailability, metabolism and excretion of ASD in rats were systematically evaluated for the first time in this study. It has been confirmed that the ultra-low oral bioavailability is due to poor gastrointestinal permeability, extensive pre-absorption degradation and biotransformation. ASD after iv administration is not only excreted by the urine and bile, but possibly undergoes complex metabolic elimination.

Metabolism and Pharmacokinetics Studies of Allyl Methyl Disulfide in Rats.

The Effects of Different Garlic-Derived Allyl Sulfides on Anaerobic Sulfur Metabolism in the Mouse Kidney

Metabolism of salvianolic acid A and antioxidant activities of its methylated metabolites.

Characterization of Chemical Constituents and Rats Metabolites of an Alkaloidal Extract of Alstonia Scholaris Leaves by Liquid Chromatography Coupled with Mass Spectrometry

Protective effect of allyl methyl disulfide on acetaminophen-induced hepatotoxicity in mice

Determination of S-Allylmercaptocysteine in Rat Plasma by LC-MS/MS and its Application to a Pharmacokinetics Study.

The Identification and Pharmacokinetic Studies of Metabolites of Salvianolic Acid B after Intravenous Administration in Rats

Metabolic and Pharmacokinetic Profiling Studies of N, N-Dimethylaniline-Heliamine in Rats by UHPLC-Q-Orbitrap MS/MS

Pharmacokinetics, Bioavailability, Excretion and Metabolism Studies of Akebia Saponin D in Rats: Causes of the Ultra-Low Oral Bioavailability and Metabolic Pathway

Allyl methyl disulfide inhibits IL-8 and IP-10 secretion in intestinal epithelial cells via the NF-кB signaling pathway

A Comprehensive Study to Determine the Residual Elimination Pattern of Major Metabolites of Amoxicillin–Sulbactam Hybrid Molecules in Rats by UPLC‒MS/MS

Identification of Metabolites of Deoxyschizandrin in Rats by UPLC–Q-TOF-MS/MS Based on Multiple Mass Defect Filter Data Acquisition and Multiple Data Processing Techniques

Study on Chemical Profiles and Metabolites of Allii Macrostemonis Bulbus As Well As Its Representative Steroidal Saponins in Rats by Ultra-Performance Liquid Chromatography Coupled with Quadrupole Time-of-flight Tandem Mass Spectrometry

Metabolic profiling and pharmacokinetic studies of alkamides, a pair of cis-trans isomers N-isobutyl-2E,4E,8Z,10E/Z-dodecatetraenamide, from Asari Radix et Rhizoma by UHPLC-Q/TOF-MS and UHPLC-MS/MS

Allyl Methyl Disulfide (AMDS) Prevents N,N-dimethyl Formamide-Induced Liver Damage by Suppressing Oxidative Stress and NLRP3 Inflammasome Activation.

Determination of alamifovir disoproxil fumarate and its active metabolite 602076 in rat plasma by LC-MS/MS: application to a pharmacokinetic study

Unraveling the in vitro and in vivo metabolism of diacetoxyscirpenol in various animal species and human using ultrahigh-performance liquid chromatography-quadrupole/time-of-flight hybrid mass spectrometry

Allyl methyl sulfide, an organosulfur compound alleviates hyperglycemia mediated hepatic oxidative stress and inflammation in streptozotocin - induced experimental rats

Metabonomic study on the effects of allicin on rats

Density Functional Theory Studies on the Chemical Reactivity of Allyl Mercaptan and Its Derivatives

Preclinical Pharmacokinetic Evaluation and Metabolites Identification of Methyl Salicylate-2-o-β-d-lactoside in Rats Using LC-MS/MS and Q-TOF-MS Methods.